S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors|
|European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)|
|Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014|
|Alexion to Present at Investor Conferences|
|Alexion Strengthens and Broadens Its Executive Leadership Team|
|Alexion Reports Second Quarter 2014 Results|
|European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia|
|Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation|
|Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting|
|NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England|
Click above to view more mutual fund data and stats for alxn - Alexion Pharmaceuticals Inc.